Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C
نویسندگان
چکیده
منابع مشابه
Danazol one Month Treatment of Thrombocytopenia in Chronic Hepatitis C
Thrombocytopenia is frequently observed in patients with chronic hepatitis C virus. Moderate and severe thrombocytopenia (<75,000/mm3) may interfere with diagnostic or therapeutic elective procedures and can be a limiting factor when considering these interventions. The aim of this study was to evaluate the efficacy of one month Danazol treatment for increasing and maintaining platelet levels i...
متن کاملDanazol in treatment of lupus thrombocytopenia.
Seven patients with systemic lupus erythematosus (SLE), persistent thrombocytopenia (TP), in whom it was considered undesirable to institute an increase in steroid or immunosuppressive agents, were treated with danazol. Five patients completed the minimum period of 8 weeks. Two patients showed early response to danazol but were switched over to cyclophosphamide or azathioprine after 4 weeks bec...
متن کاملViremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C.
BACKGROUND & AIMS In chronic hepatitis C, interferon alfa induces sustained remission in less than 30% of treated patients. The aim of this study is to analyze viral status early after initiation interferon therapy as a predictor of treatment outcome. METHODS One hundred eighty-one patients with chronic hepatitis C who had been treated with interferon alfa for 12 months (median follow-up, 49 ...
متن کاملThrombocytopenia in Patients with Chronic Hepatitis C Virus Infection
Thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection is a major problem. The pathophysiology is multifactorial, with auto-immunogenicity, direct bone marrow suppression, hypersplenism, decreased production of thrombopoietin and therapeutic adverse effect all contributing to thrombocytopenia in different measures. The greatest challenge in the care of chronic HCV patients ...
متن کاملTreatment of autoimmune thrombocytopenia in a case of chronic hepatitis C with ursodeoxycholic acid.
Pegylated interferon (PEG-IFN) alpha and ribavirin therapy has become the standard treatment in chronic hepatitis C virus (HCH)-infected patients. While thrombocytopenia associated with IFN use is frequently observed among these patients, autoimmune thrombocytopenia is one of the rarely observed adverse effects. In the present report, we present a case with chronic HCV infection in which autoim...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicine Science | International Medical Journal
سال: 2016
ISSN: 2147-0634
DOI: 10.5455/medscience.2015.04.8371